CH3 BIOSYSTEMS LLC
Featured in Peer-Reviewed Research
How the E0771 Cell Line from CH3 Biosystems
Powered a Landmark Brain Cancer Study
Published in Cell Reports, March 2025 | Golomb et al.
Blog post by Pranitha Bhuthkuri
The Big Picture
A landmark 2025 study published in Cell Reports used the E0771 breast cancer cell line, sourced directly from CH3 Biosystems LLC (Amherst, NY), as the biological foundation for a series of groundbreaking discoveries about brain cancer and the gut.
The research team, led by Dr. Siyuan Zhang at UT Southwestern Medical Center and the University of Notre Dame, set out to answer a deceptively simple question: does the health of your gut microbiome affect how aggressively breast cancer spreads to the brain? The answer they found was yes — profoundly so — and the E0771 cell line made it possible to prove it.
What the Study Was About
Brain metastasis (BrMet) — when cancer cells travel from a primary tumor to the brain — is one of the most dangerous and poorly understood stages of breast cancer progression. The Zhang Lab wanted to map, in exquisite molecular detail, how the brain’s immune system responds as tumors grow, and whether gut health shapes that response.
To do this, they divided mice into two groups: one received a broad-spectrum antibiotic cocktail to disrupt their gut microbiome (causing ‘gut dysbiosis’), and the other served as healthy controls. Both groups then received breast cancer cells to induce experimental brain metastasis. Using cutting-edge single-cell RNA sequencing (CITE-seq), the team profiled every immune cell in the brain at four precise time points.
Published: Golomb SM et al. “Temporal dynamics of immune cell transcriptomics in brain metastasis progression influenced by gut microbiome dysbiosis.” Cell Reports 44, 115356 (March 25, 2025). DOI: 10.1016/j.celrep.2025.115356
The E0771 Cell Line: Sourced from CH3 Biosystems
The E0771 is a mammary adenocarcinoma cell line of female mouse origin, derived from the C57BL/6 genetic background — making it uniquely compatible with immunocompetent mouse models. It is one of the most widely used syngeneic breast cancer cell lines in cancer research worldwide.
For this study, the research team purchased the E0771 cell line directly from CH3 Biosystems LLC in Amherst, New York (SKU: 940001-Vial), as formally documented in the paper’s Key Resources Table. The choice of cell source is a critical methodological decision that affects the reproducibility and credibility of the entire study.
Why Syngeneic Matters
The E0771 cell line is syngeneic with the C57BL/6 mouse strain — meaning the tumor cells and the host share the same genetic background. This is essential for immune studies. In a syngeneic model, the mouse’s immune system mounts a real immune response, rather than simply rejecting foreign tissue. If the researchers had used a different cell type, the mice would have needed to be immunodeficient — making it impossible to study immune dynamics at all.
How Researchers Modified E0771: Creating E0771.Br
The researchers did not use the standard E0771 cells off the shelf. Instead, they developed a specialized, two-step modified derivative called E0771.Br — a ‘brain-seeking’ variant engineered specifically for modeling brain metastasis with precision.
Step 1 — In Vivo Selection for Brain Tropism
The first challenge was that standard E0771 cells do not reliably colonize the brain when injected into a living mouse. To overcome this, the team put the E0771 cells through one round of in vivo selection: injecting them into mice and harvesting only the cells that successfully grew in the brain. This selected subpopulation — cells with a proven biological affinity for brain tissue — became the E0771.Br line.
This process is methodologically elegant because it uses natural biological selection, rather than genetic engineering, to identify cells inherently predisposed to brain colonization. The result is a cell line that behaves realistically in vivo, closely mimicking what happens during actual breast cancer brain metastasis in patients.
Step 2 — Fluorescent Labeling with mCherry
Once the brain-seeking E0771.Br line was established from the original E0771 stock, the cells were genetically modified using lentiviral transduction to stably express mCherry — a bright red fluorescent protein. When these cells form tumors in the brain, those tumors glow red under a fluorescence stereoscope, allowing researchers to count every metastatic lesion immediately after brain extraction with no ambiguity.
Quality Control
The E0771.Br cells were maintained in RPMI media with 10% FBS and 1% Penicillin/Streptomycin. They were certified negative for a comprehensive panel of mouse pathogens by IDEXX BioResearch Inc. Genetic integrity was tracked using CellCheck Mouse Plus to prevent drifting or cross-contamination — all starting from the documented, quality-controlled E0771 stock from CH3 Biosystems.
How E0771.Br Cells Were Used: The Experimental Model
To generate experimental brain metastasis, the researchers injected exactly 300,000 mCherry-labeled E0771.Br cells (derived from the CH3 Biosystems E0771 stock) into the left internal carotid artery of adult female C57BL/6 mice. The carotid artery provides direct blood flow toward the brain, replicating the physiological route that metastatic cancer cells take in human patients.
By injecting a precise, standardized number of cells from a consistent, characterized cell line, the researchers ensured reproducibility across all animals and experiments. The E0771‘s reliability was essential to this consistency.
What They Discovered: Key Findings
The use of a reliable, consistent brain metastasis model — built on the E0771 cell line from CH3 Biosystems — allowed the team to generate four major discoveries:
Finding 1: Disrupted Gut Health Fuels Brain Tumor Growth
Mice with antibiotic-induced gut dysbiosis developed significantly more brain metastases than mice with healthy microbiomes (p = 0.0008). When the researchers restored gut microbiome diversity using fecal matter transplantation (FMT), the increased tumor burden was completely reversed — proving that microbiome diversity was the specific driver of increased cancer progression.
Finding 2: The Immune Timeline Is Thrown Off by Gut Dysbiosis
In healthy mice, Ly6C+ monocytes mounted a strong interferon (IFN) response at mid-stage metastasis (Day 8). In dysbiotic mice, this response was delayed until late-stage (Day 14) — arriving after tumors had already established themselves more firmly. This ‘asynchronous’ immune response represents a window during which tumors can grow with less opposition.
Finding 3: Gut Dysbiosis Triggers Highly Inflammatory Microglia
By late-stage metastasis, mice with gut dysbiosis had a dramatically higher proportion of TNF-High microglia — brain immune cells expressing high levels of tumor necrosis factor (TNF), CCL2, CCL3, CCL4, and IL-1b. RNA velocity analysis showed these inflammatory microglia were differentiating faster in dysbiotic mice, as though the disrupted gut was actively pushing brain immune cells toward a more aggressive, inflammatory state.
Finding 4: The Immune System Becomes a Tumor Ally
When researchers depleted CD3+ T cells or removed microglia from dysbiotic mice, brain tumor burden decreased significantly. Under gut dysbiosis, these immune cells — which normally fight cancer — were instead acting as tumor promoters. The gut microbiome was functioning as a switch that determined whether immune cells fought for or against the host.
Why E0771 Was the Right Choice for This Study
- Female origin: The E0771‘s female C57BL/6 origin ensured biological and hormonal compatibility with the female mice used throughout.
- Syngeneic immunocompetent modeling: The E0771 is syngeneic with C57BL/6 mice, allowing use of immunologically intact hosts — essential for studying the immune response to metastasis.
- Proven adaptability: The E0771‘s biology supported in vivo selection to generate a brain-tropic derivative, demonstrating its inherent plasticity beyond its base form.
- Lentiviral transduction compatibility: The E0771 cells successfully accepted stable mCherry labeling — not all cell lines are amenable to this, making it a non-trivial advantage.
- Pathogen-free certification: The CH3 Biosystems E0771 stock allowed researchers to start with a certified, clean baseline — ensuring observed effects were due to their manipulations, not contamination.
- Reproducibility: Using the commercially documented E0771 from CH3 Biosystems means other labs can reproduce this work using the same starting material — a cornerstone of scientific integrity.
The Bottom Line
The 2025 Cell Reports study by Golomb et al. represents a significant advance in our understanding of how gut health shapes the brain’s immune response to cancer. None of it would have been possible without the E0771 cell line from CH3 Biosystems — a scientifically validated, consistently characterized starting point the research team could build upon and trust.
At CH3 Biosystems, we are proud that our E0771 cell line is chosen by leading academic institutions to power studies of this caliber. The E0771 (SKU: 940001-Vial) is available now.
Ready to advance your research?
Order the E0771 today | SKU: 940001-Vial | ch3biosystems.com
Contact: info@ch3biosystems.com | CH3 Biosystems LLC, Amherst, NY
